Testing a four-drug combination for advanced bowel cancer

This trial is testing a new combination of four medications—chidamide, regorafenib, iparomlimab, and tuvonralimab—for people with advanced colorectal cancer that has not responded well to at least two previous treatment regimens. The researchers believe that combining these four drugs, which work in different ways, may be more effective than current standard treatments. This is a Phase 2 study, meaning the medications are past early safety testing but researchers still want to understand how well this combination works and what side effects it causes.

People with advanced colorectal cancer often run out of good treatment options after their cancer stops responding to the first two or three standard therapies. Current treatments at this stage only help a small number of patients and for a short period of time. Researchers believe that combining medications that attack cancer through different mechanisms—including targeting blood vessel growth and boosting the immune system—may offer better results than any single drug alone.